Scarica l'app Stockscreener
354.54
0.59%
2.07
Dopo l'orario di chiusura:
354.54
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$352.47
Aprire:
$350.49
Volume 24 ore:
221.09K
Relative Volume:
0.58
Capitalizzazione di mercato:
$9.49B
Reddito:
$2.59B
Utile/perdita netta:
$168.80M
Rapporto P/E:
58.36
EPS:
6.0748
Flusso di cassa netto:
$357.20M
1 W Prestazione:
+5.92%
1M Prestazione:
+19.73%
6M Prestazione:
+18.20%
1 anno Prestazione:
+34.19%
Intervallo 1D:
$347.86
$355.85
Intervallo di 1 settimana:
$325.31
$355.85
Portata 52W:
$236.73
$355.85
Bio Rad Laboratories Inc Stock (BIO) Company Profile
Nome
Bio Rad Laboratories Inc
Settore
Industria
Telefono
(510) 724-7000
Indirizzo
1000 ALFRED NOBEL DRIVE, HERCULES
Compare BIO vs ABT, SYK, MDT, BSX, EW
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
BIO
Bio Rad Laboratories Inc
|
354.54 | 8.47B | 2.59B | 168.80M | 357.20M | 6.0748 |
ABT
Abbott Laboratories
|
108.62 | 182.00B | 46.59B | 5.41B | 7.38B | 3.0938 |
SYK
Stryker Corp
|
345.81 | 129.09B | 25.27B | 3.34B | 4.57B | 8.6334 |
MDT
Medtronic Plc
|
89.41 | 107.81B | 36.36B | 4.84B | 5.43B | 3.7261 |
BSX
Boston Scientific Corp
|
50.46 | 67.64B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
92.03 | 47.81B | 6.30B | 1.07B | 1.09B | 1.8406 |
Bio Rad Laboratories Inc Stock (BIO) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-04-07 | Downgrade | Citigroup | Buy → Neutral |
| 2024-10-01 | Aggiornamento | Citigroup | Neutral → Buy |
| 2024-08-28 | Iniziato | Wells Fargo | Equal Weight |
| 2024-06-03 | Ripresa | Jefferies | Hold |
| 2024-04-03 | Downgrade | Citigroup | Buy → Neutral |
| 2023-12-07 | Iniziato | UBS | Buy |
| 2023-06-16 | Iniziato | Wells Fargo | Overweight |
| 2022-12-07 | Iniziato | RBC Capital Mkts | Outperform |
| 2022-08-25 | Iniziato | Credit Suisse | Outperform |
| 2022-01-28 | Reiterato | Citigroup | Buy |
| 2020-01-08 | Iniziato | Wells Fargo | Overweight |
| 2020-01-07 | Iniziato | Citigroup | Buy |
| 2018-10-17 | Iniziato | Goldman | Buy |
| 2018-09-20 | Iniziato | Morgan Stanley | Equal-Weight |
| 2018-02-16 | Downgrade | CL King | Buy → Neutral |
| 2017-07-13 | Iniziato | Wells Fargo | Outperform |
| 2017-06-28 | Aggiornamento | Deutsche Bank | Hold → Buy |
| 2017-01-18 | Iniziato | Deutsche Bank | Hold |
| 2016-10-13 | Iniziato | CL King | Buy |
| 2015-05-06 | Reiterato | Jefferies | Buy |
| 2009-12-18 | Iniziato | Maxim Group | Buy |
| 2009-11-06 | Iniziato | Jefferies & Co | Buy |
| 2009-07-17 | Iniziato | Soleil | Buy |
| 2007-09-26 | Iniziato | Banc of America Sec | Buy |
| 2007-02-23 | Downgrade | Robert W. Baird | Outperform → Neutral |
Mostra tutto
Bio Rad Laboratories Inc Borsa (BIO) Ultime notizie
BIO|Bio Rad Laboratories Inc|Price:316.410|Chg%:+1.950 - TradingKey
Bio Rad Laboratories Inc (BIO) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Bio Rad Laboratories Inc (BIO) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Bio Rad Laboratories Inc (BIO) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Bio Rad Laboratories Inc (BIO) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
BIO|Bio Rad Laboratories Inc|Price:314.460|Chg%:-1.760 - TradingKey
TradingKey - TradingKey
Bio-Rad Laboratories (BIO) Q2 2025 Earnings ReportResults, Call & Slides - TipRanks
Insight Molecular Diagnostics Ord Shs (IMDX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Blood Transfusion Diagnostics Market Size to Hit USD 8.67 Billion by 2035 as Automated Testing and AI-Driven Blood Safety Solutions Accelerate Growth | SNS Insider - GlobeNewswire Inc.
Bio Rad Laboratories Inc (BIO) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Bio-Rad Laboratories, Inc. (BIO) Stock forecasts - Yahoo Finance Singapore
Bio-Rad Laboratories (BIO) Q3 2025 Earnings ReportResults, Call & Slides - TipRanks
Bio-Rad Laboratories Inc (BIO) Stock Up 3.4% and Still Undervalued -- GF Score: 72/100 - GuruFocus
Bio-Rad to Report Second-Quarter 2026 Financial Results on Tuesday, August 4, 2026 - BioSpace
Press Release: Bio-Rad to Report Second-Quarter 2026 Financial Results on Tuesday, August 4, 2026 - Moomoo
Bio-Rad will discuss Q2 results at 5 p.m. ET on Aug. 4 - Stock Titan
Bio-Rad to report Q2 2026 results, host conference call - Bitget
Bio-Rad Laboratories stock holds on to year-end earnings context - Ad-hoc-news.de
Bio-Rad Laboratories (BIO) Experiences Minor Decline Amid Compet - GuruFocus
Bio Rad Laboratories (BIO) Stock Looks Fairly Valued After A 57% Slide - Sahm
Bio-Rad Q1 2026 Earnings: EPS Misses Estimates by 5.68%, Stock Edges Higher on Resilient Business TrendsRevenue Breakdown Analysis - po-news-eg.net
(BIO) Volatility Zones as Tactical Triggers - Stock Traders Daily
ETFs Investing in Bio-Rad Laboratories, Inc. Class A Stocks - TradingView
BIO5368763 Bond Coupon Profile — Rate & Payments - TradingView
BIO5368763 Bond Risk Profile - TradingView
BIO5368763 Bond Profile — Key Metrics - TradingView
BIO5368765 Bond Profile — Key Metrics - TradingView
BIO5368765 Bond Risk Profile - TradingView
BIO5368765 Bond Coupon Profile — Rate & Payments - TradingView
Bio-Rad unveils Vericheck ddPCR kits for QX700 QC - Select Science
Price to earnings forward of Bio-Rad Laboratories, Inc. – NYSE:BIO - TradingView
Price to earnings forward of Bio-Rad Laboratories, Inc. – BOATS:BIO - TradingView
Bio Rad Laboratories (BIO) Launches New ddPCR Kits Following A Fair Value Debate - Sahm
BIO Q1 2026 Earnings: EPS Falls Short of Expectations, Shares Edge LowerEPS Revision Trend - dars.gov.et
Is It Too Late to Buy Bio-Rad Laboratories Inc (BIO) After 4.7% Rally? GF Value Says Undervalued - GuruFocus
Bio-Rad launches Vericheck ddPCR Kits compatible with QX700 platform for biopharma quality control and cell and gene therapy workflows - News-Medical
Bio-Rad Releases New Quality Control Kits for Cell and Gene Therapy - Clinical Lab Products
Bio-Rad Launches Vericheck ddPCR Kits Compatible with QX700 Platform for Biopharma Quality Control and Cell and Gene Therapy Workflows - Cambridge Network
Bio-Rad Laboratories outlines its diagnostics and life science strategy for long-term growth - Ad-hoc-news.de
IVD Quality Control Market Size, Share | Industry Report [2034] - Fortune Business Insights
BIOBio-Rad Laboratories Inc Volatility & Greeks - Finviz
Price to sales forward of Bio-Rad Laboratories, Inc. – NYSE:BIO - TradingView
BIO.B Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
Bio-Rad Laboratories outlines long-term growth drivers as life science demand evolves - Ad-hoc-news.de
Bio-Rad: Activist Involvement Highlights Value-Unlocking Potential (NYSE:BIO) - Seeking Alpha
BIO.B Technical Analysis & Stock Price Forecast - Intellectia AI
Bio-Plex Pro Human Cytokine Assays from Bio-Radmultiplex panels for immune research - ad-hoc-news.de
Bio Rad Laboratories (BIO) Following ddPCR Expansion Narrative Looks Fully Valued - Sahm
Bio-Rad Laboratories, Inc. (BIO) Stock Analysis: Evaluating Growth Amidst Stable Price Movements - DirectorsTalk Interviews
Bio-Rad Laboratories, Inc. Class B Actuals & Estimates (LSX:862449) - TradingView
Bio Rad Laboratories Inc Azioni (BIO) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.27%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):